Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
136.9 USD | -0.62% | +4.62% | +4.81% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 54% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The firm trades with high earnings multiples: 29.21 times its 2024 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.81% | 13.86B | C+ | ||
-2.82% | 103B | B+ | ||
+0.68% | 95.71B | B+ | ||
+1.37% | 22.02B | B | ||
-17.42% | 20.9B | B+ | ||
-9.28% | 17.85B | A- | ||
-42.83% | 16.21B | A- | ||
-15.67% | 15.52B | B | ||
+32.45% | 12.04B | C+ | ||
-25.88% | 8.08B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NBIX Stock
- Ratings Neurocrine Biosciences, Inc.